Financing ·
Alto Neuroscience, Inc. entered into an underwriting agreement on July 13, 2026, to conduct a registered direct…
ANROAlto Neuroscience, Inc.
Alto Neuroscience, Inc. entered into an underwriting agreement on July 13, 2026, to conduct a registered direct offering of 3,776,436 shares of common stock at $26.48 per share. The company expects net proceeds of approximately $93.9 million to fund the clinical development of ALTO-207, specifically an additional Phase 3 trial for treatment-resistant depression, and for general working capital. The offering is expected to close on July 14, 2026. Alto Neuroscience, Inc. is a biotechnology company focused on developing neuroscience-based therapeutics.